AOD-9604 dosage protocols leverage this synthetic 16‑amino‑acid fragment (Tyr‑hGH 177–191) to support lipolysis (fat breakdown) and inhibit lipogenesis (fat storage) without elevating IGF‑1 levels or causing insulin resistance. Clinical trials have demonstrated that AOD‑9604 exhibits a placebo‑like safety profile in obese adults, making it a well‑tolerated option for metabolic support. This educational protocol outlines a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.
